专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120190113A1 Macroporous Microcarrier Specific to Liver Cell, Preparation Method and Use Thereof 审中-公开
标题翻译：特异于肝细胞的大孔微载体，其制备方法和用途
公开(公告)号：US20120190113A1
公开(公告)日：2012-07-26
申请号：US13389595
申请日：2010-04-17
申请人： Yi Gao , Mingxin Pan , Duhui Gong , Zhi Zhang , Huancheng Zhou , Zhiwei Hu
发明人： Yi Gao , Mingxin Pan , Duhui Gong , Zhi Zhang , Huancheng Zhou , Zhiwei Hu
IPC分类号： C12N5/071
CPC分类号： C08B37/003 , C08H1/00 , C08J3/12 , C08J9/0061 , C08J9/286 , C08J2389/00 , C08J2405/00 , C08L5/08 , C08L89/00 , C12N5/0075 , C12N5/067 , C12N2531/00 , C12N2533/50 , C12N2533/72 , C08L2666/26
摘要： The present invention provides a macroporous microcarrier specific to hepatocytes using silk fibroin and galactosylated chitosan as main raw material, a preparation method thereof, and application for hepatocyte culture under the culture condition of microgravity rotation. The macroporous microcarrier s a sphere prepared from silk fibroin and galactosylated chitosan under the effect of crosslinker, wherein based on the total weight of the sphere, the content of silk fibroin is 50-80 wt % and the content of galactosylated chitosan is 15-40 wt %. The diameter of the microcarrier is 200-500 μm, and the aperture of the microcarrier is 40-80 μm. Compared with normal solid scaffold material, the microcarrier provided by the present invention has larger surface area/volume ratio and, a sinus gap structure extremely similar with in-vivo liver sinus structure, therefore it is more conducive to adhering of the hepatocytes on the scaffold material, contacting between cells, transporting oxygen and nutrient components and excreting metabolic products.
摘要翻译：本发明提供使用丝素蛋白和半乳糖基化壳聚糖作为主要原料的肝细胞特异性的大孔微载体，其制备方法，以及微重力旋转培养条件下肝细胞培养的应用。由丝素蛋白和半乳糖基化壳聚糖制备的大孔微球体在交联剂的作用下，其中以球体总重为基准，丝素蛋白含量为50-80重量％，半乳糖基化壳聚糖含量为15-40重量％％。微载体的直径为200-500μm，微载体的孔径为40-80μm。与正常的固体支架材料相比，本发明提供的微载体具有较大的表面积/体积比，以及与体内肝窦结构非常相似的窦间隙结构，因此更有利于肝细胞在支架上的粘附材料，细胞之间的接触，运输氧气和营养成分并排出代谢产物。

2. 发明申请

US20120045833A1 Bioreactor, control system and control method thereof 审中-公开
标题翻译：生物反应器，控制系统及其控制方法
公开(公告)号：US20120045833A1
公开(公告)日：2012-02-23
申请号：US13130582
申请日：2010-04-16
申请人： Yi Gao , Huangcheng Zhou , Yan Wang , Xiaoping Xu , Mingxin Pan
发明人： Yi Gao , Huangcheng Zhou , Yan Wang , Xiaoping Xu , Mingxin Pan
IPC分类号： C12N5/02 , C12M1/12
CPC分类号： C12M23/06 , C12M25/12 , C12M27/14
摘要： A bioreactor includes a cylinder, a mandrel and a filter film. The cylinder includes two end walls and a circumferential wall interconnected with the both end walls; the two end walls and circumferential wall define together a reaction chamber. The mandrel is disposed between the two end walls. The mandrel has an inlet path and an outlet path provided on its both ends; the filter film wraps the mandrel to prevent passage of the first kind of substance while permit the passage of the second kind of substance; a gap is defined between the filter film and mandrel; at least one portion of the filter film is tied so as to divide the gap into multiple separate and isolated gap regions to prevent the second fluid from direct exiting from the outlet path through the gap. Also disclosed are control system and method for the bioreactor.
摘要翻译：生物反应器包括圆筒，心轴和过滤膜。气缸包括两个端壁和与两个端壁相互连接的圆周壁; 两个端壁和圆周壁将反应室一起限定在一起。心轴设置在两个端壁之间。心轴具有设置在其两端的入口路径和出口路径; 过滤膜包裹心轴以防止第一种物质的通过，同时允许第二种物质的通过; 在过滤膜和心轴之间限定间隙; 过滤膜的至少一部分被捆扎以将间隙分成多个分离和隔离的间隙区域，以防止第二流体通过间隙从出口路径直接排出。还公开了用于生物反应器的控制系统和方法。

4. 发明申请

US20130085181A1 PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：药物制剂
公开(公告)号：US20130085181A1
公开(公告)日：2013-04-04
申请号：US13485032
申请日：2012-05-31
申请人： Yi Gao , Tzuchi R. Ju , Dennis Y. Lee , Nicole Nguyen , Huailiang Wu
发明人： Yi Gao , Tzuchi R. Ju , Dennis Y. Lee , Nicole Nguyen , Huailiang Wu
IPC分类号： A61K31/192
CPC分类号： A61K31/192 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K31/194 , A61K47/38
摘要： The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.
摘要翻译：本发明提供一种在亲水性聚合物基质中包含活性剂的改性释放制剂，其中活性剂是非诺贝酸盐，其中制剂在体外溶出中的释放速率基本上与溶出介质的离子强度无关。

5. 发明申请

US20120264780A1 SOLID COMPOSITIONS 有权
标题翻译：固体组合物
公开(公告)号：US20120264780A1
公开(公告)日：2012-10-18
申请号：US13156793
申请日：2011-06-09
申请人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson
发明人： Simon Kullmann , Ulrich Westedt , Mirko Pauli , Rudolf Schroeder , Gerd Woehrle , Tanja Heitermann , Renato Koenig , Madlen Thiel , Yi Gao , Jianwei Wu , Bryan K. Erickson
IPC分类号： A61K31/4545 , A61P31/14 , A61K31/4184
CPC分类号： C07D401/14 , C07D403/14 , C07D417/14
摘要： The present invention features solid compositions comprising Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB or IC, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
摘要翻译：本发明的特征在于包含无定形形式的化合物1A，IB或IC或其药学上可接受的盐的固体组合物。在一个实施方案中，将化合物1A，IB或IC或其药学上可接受的盐配制在包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体中。

6. 发明申请

US20120220562A1 Anti-Viral Compounds 审中-公开
公开(公告)号：US20120220562A1
公开(公告)日：2012-08-30
申请号：US13404429
申请日：2012-02-24
申请人： David A DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , Allan C. Krueger , John T. Randolph , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Yi Gao , Dachun Liu , John K. Pratt , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , Rolf Wagner , David A. Betebenner , Kathy Sarris , Kevin R. Woller , William A. Carroll
发明人： David A DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , Allan C. Krueger , John T. Randolph , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Yi Gao , Dachun Liu , John K. Pratt , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , Rolf Wagner , David A. Betebenner , Kathy Sarris , Kevin R. Woller , William A. Carroll
IPC分类号： A61K31/496 , A61K31/506 , A61K31/4545 , A61P31/14 , C07D403/14 , C07D401/14 , C07D405/14 , A61K31/4178 , A61K31/454
CPC分类号： C07D403/14 , C07D207/16
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

7. 发明申请

US20060280791A1 Pharmaceutical formulations 审中-公开
标题翻译：药物制剂
公开(公告)号：US20060280791A1
公开(公告)日：2006-12-14
申请号：US11399983
申请日：2006-04-07
申请人： Tzuchi Ju , Claudia Davila , Kevin Engh , Yi Gao , Linda Gustavson , Shyamala Jayaraman , David LeBlond , Dennis Lee , Tong Zhu
发明人： Tzuchi Ju , Claudia Davila , Kevin Engh , Yi Gao , Linda Gustavson , Shyamala Jayaraman , David LeBlond , Dennis Lee , Tong Zhu
IPC分类号： A61K31/192 , A61K9/20
CPC分类号： A61K9/5026 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K31/192
摘要： The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
摘要翻译：本发明涉及包含含有2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸中的至少一种的活性剂，2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸或缓冲的2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸。

8. 外观设计

USD981214S1 Limiter of tension tube 有权
公开(公告)号：USD981214S1
公开(公告)日：2023-03-21
申请号：US29859378
申请日：2022-11-09
申请人： Yi Gao
设计人： Yi Gao

9. 发明授权

US08691938B2 Anti-viral compounds 有权
标题翻译：抗病毒化合物
公开(公告)号：US08691938B2
公开(公告)日：2014-04-08
申请号：US12813301
申请日：2010-06-10
申请人： David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , Allan C. Krueger , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Yi Gao , Dachun Liu , John K. Pratt , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , Rolf Wagner , Michael D. Tufano , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi
发明人： David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , Allan C. Krueger , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Yi Gao , Dachun Liu , John K. Pratt , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , Rolf Wagner , Michael D. Tufano , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi
IPC分类号： C07K16/00 , A61K31/66
CPC分类号： C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
摘要翻译：描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

10. 发明授权

US08216725B2 Electrolyte for batteries and battery packs 有权
标题翻译：电池用电池和电池组
公开(公告)号：US08216725B2
公开(公告)日：2012-07-10
申请号：US12352981
申请日：2009-01-13
申请人： Yi Gao , JiangMin Zhu
发明人： Yi Gao , JiangMin Zhu
IPC分类号： H01M6/16
CPC分类号： H01M10/0567 , H01M10/0525 , H01M10/0568 , H01M10/4235
摘要： Electrolyte for lithium secondary batteries and battery packs includes a lithium salt, a non-aqueous solvent, and an additive. The additive includes two or more members selected from the group consisting of substances A, B and C, wherein A includes one or more fused ring compounds and fused heterocyclic compounds, B includes an alkoxy aromatic compound, and C includes halogenated borane-based salt.
摘要翻译：锂二次电池和电池组的电解液包括锂盐，非水溶剂和添加剂。添加剂包括选自物质A，B和C中的两种或多种，其中A包括一个或多个稠环化合物和稠合杂环化合物，B包括烷氧基芳族化合物，C包括卤代硼烷基盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式